[go: up one dir, main page]

MX2020003415A - Compuestos de benzoxacepina oxazolidinona y métodos de uso. - Google Patents

Compuestos de benzoxacepina oxazolidinona y métodos de uso.

Info

Publication number
MX2020003415A
MX2020003415A MX2020003415A MX2020003415A MX2020003415A MX 2020003415 A MX2020003415 A MX 2020003415A MX 2020003415 A MX2020003415 A MX 2020003415A MX 2020003415 A MX2020003415 A MX 2020003415A MX 2020003415 A MX2020003415 A MX 2020003415A
Authority
MX
Mexico
Prior art keywords
pi3k
methods
formula
benzoxacepine
oxazolidinone compounds
Prior art date
Application number
MX2020003415A
Other languages
English (en)
Other versions
MX388533B (es
Inventor
Emily Hanan
Calum Macleod
Robert Andrew Heald
Richard Elliott
Steven T Staben
Marie-Gabrielle Braun
Original Assignee
F Hoffmann ­La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann ­La Roche Ag filed Critical F Hoffmann ­La Roche Ag
Publication of MX2020003415A publication Critical patent/MX2020003415A/es
Publication of MX388533B publication Critical patent/MX388533B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B43/00—Formation or introduction of functional groups containing nitrogen
    • C07B43/06—Formation or introduction of functional groups containing nitrogen of amide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En el presente documento se describen compuestos de benzoxacepina oxazolidinona con actividad o función moduladora de fosfoinosítido 3 cinasa (PI3K) que tienen la estructura de fórmula I: (ver fórmula I) o estereoisómeros, tautómeros, o sales farmacéuticamente aceptable de los mismos, y con los sustituyentes y características estructurales descritas en el presente documento. También se describen composiciones farmacéuticas y medicamentos que incluyen los compuestos de fórmula I, así como métodos para usar dichos moduladores de PI3K, solos o en combinación con otros agentes terapéuticos, para tratar enfermedades o afecciones que están mediadas o que son dependientes de la desregulación de PI3K.
MX2020003415A 2015-07-02 2016-07-01 Compuestos de benzoxacepina oxazolidinona y métodos de uso. MX388533B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562188029P 2015-07-02 2015-07-02
PCT/EP2016/065455 WO2017001645A1 (en) 2015-07-02 2016-07-01 Benzoxazepin oxazolidinone compounds and methods of use

Publications (2)

Publication Number Publication Date
MX2020003415A true MX2020003415A (es) 2021-12-07
MX388533B MX388533B (es) 2025-03-20

Family

ID=56292756

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017016344A MX372624B (es) 2015-07-02 2016-07-01 Compuestos de benzoxacepina oxazolidinona y metodos de uso
MX2020003415A MX388533B (es) 2015-07-02 2016-07-01 Compuestos de benzoxacepina oxazolidinona y métodos de uso.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017016344A MX372624B (es) 2015-07-02 2016-07-01 Compuestos de benzoxacepina oxazolidinona y metodos de uso

Country Status (32)

Country Link
US (7) US9650393B2 (es)
EP (5) EP3567045B1 (es)
JP (4) JP6523490B2 (es)
KR (2) KR102306071B1 (es)
CN (4) CN111909173B (es)
AR (1) AR105238A1 (es)
AU (2) AU2016287463B2 (es)
CA (1) CA2982708C (es)
CL (1) CL2017003436A1 (es)
CO (1) CO2017011038A2 (es)
CR (1) CR20170563A (es)
DK (1) DK3317284T3 (es)
ES (2) ES2764497T3 (es)
HR (1) HRP20192349T1 (es)
HU (1) HUE046756T2 (es)
IL (3) IL255200B (es)
LT (1) LT3317284T (es)
MA (3) MA54252A (es)
MX (2) MX372624B (es)
MY (1) MY195002A (es)
PE (2) PE20181021A1 (es)
PH (2) PH12017502425A1 (es)
PL (2) PL3567045T3 (es)
PT (1) PT3317284T (es)
RS (1) RS59740B1 (es)
RU (1) RU2730529C2 (es)
SG (1) SG10201913980SA (es)
SI (1) SI3317284T1 (es)
TW (4) TW202108592A (es)
UA (1) UA121678C2 (es)
WO (1) WO2017001645A1 (es)
ZA (1) ZA201808370B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9643980B2 (en) 2015-07-02 2017-05-09 Genentech, Inc. Benzoxazepin oxazolidinone compounds and methods of use
WO2017004500A1 (en) 2015-07-02 2017-01-05 Genentech, Inc. Bicyclic lactams and methods of use thereof
TW202108592A (zh) * 2015-07-02 2021-03-01 瑞士商赫孚孟拉羅股份公司 苯并氧氮呯噁唑啶酮化合物及其用途
WO2017042182A1 (en) 2015-09-08 2017-03-16 F. Hoffmann-La Roche Ag Tricyclic pi3k inhibitor compounds and methods of use
TW201813963A (zh) 2016-09-23 2018-04-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201815787A (zh) 2016-09-23 2018-05-01 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
TW201825465A (zh) 2016-09-23 2018-07-16 美商基利科學股份有限公司 磷脂醯肌醇3-激酶抑制劑
CN109843886B (zh) 2016-10-17 2022-04-19 豪夫迈·罗氏有限公司 二环吡啶酮内酰胺及其使用方法
SI3555107T1 (sl) 2016-12-15 2021-07-30 F. Hoffmann-La Roche Ag Postopek za pripravo (S)-2-((2-((S)-4(difluorometil)-2-oksooksazolidin-3-il)-5,6-dihidrobenzo (f)imidazo(1,2-d)(1,4)oksazepin-9-il)amino) propanamida
US11072607B2 (en) 2016-12-16 2021-07-27 Genentech, Inc. Inhibitors of RIP1 kinase and methods of use thereof
US20180339997A1 (en) 2017-04-28 2018-11-29 Genentech, Inc. Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production
WO2019204537A1 (en) 2018-04-20 2019-10-24 Genentech, Inc. N-[4-oxo-2,3-dihydro-1,5-benzoxazepin-3-yl]-5,6-dihydro-4h-pyrrolo[1,2-b]pyrazol e-2-carboxamide derivatives and related compounds as rip1 kinase inhibitors for treating e.g. irritable bowel syndrome (ibs)
AU2019276514B2 (en) * 2018-05-30 2023-12-14 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Inhibitor containing tricyclic derivative, preparation method therefor, and application thereof
AU2019310335A1 (en) * 2018-07-23 2021-02-11 F. Hoffmann-La Roche Ag Methods of treating cancer with PI3K inhibitor, GDC-0077
WO2020076432A1 (en) 2018-10-08 2020-04-16 Genentech, Inc. Methods of treating cancer with pi3k alpha inhibitors and metformin
CN109265408B (zh) * 2018-12-11 2020-09-01 上海皓元生物医药科技有限公司 二氟甲基取代噁烷-2-酮的合成方法
SG11202106635WA (en) 2018-12-21 2021-07-29 Daiichi Sankyo Co Ltd Combination of antibody-drug conjugate and kinase inhibitor
CN120172965A (zh) * 2019-05-27 2025-06-20 君实润佳(上海)医药科技有限公司 含有稳定重同位素的酰胺官能团的化合物及其应用
IL290789B1 (en) 2019-08-26 2025-05-01 Arvinas Operations Inc Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents
WO2021088845A1 (zh) * 2019-11-04 2021-05-14 贝达药业股份有限公司 咪唑烷酮类化合物及其制备方法与应用
WO2021104146A1 (zh) * 2019-11-25 2021-06-03 上海翰森生物医药科技有限公司 含三并环类衍生物的盐或晶型及其药物组合物
CN112830935B (zh) * 2019-11-25 2023-12-22 上海翰森生物医药科技有限公司 含三并环类衍生物自由碱的晶型及其药物组合物
WO2021113219A1 (en) 2019-12-03 2021-06-10 Genentech, Inc. Combination therapies for treatment of breast cancer
MX2023006793A (es) 2020-12-11 2023-06-20 Genentech Inc Tratamientos conjuntos para tratamiento de cancer her2.
EP4286391A4 (en) * 2021-01-29 2025-01-15 Medshine Discovery Inc. TRICYCLIC COMPOUNDS AND THEIR USE
KR20240007187A (ko) 2021-05-13 2024-01-16 베타 파머수티컬 컴퍼니 리미티드 이미다졸리디논류 화합물의 다형체, 제조 방법 및 이의 용도
CA3220273A1 (en) 2021-05-28 2022-12-01 Genentech, Inc. Process for the preparation of benzoxazepin oxazolidinone compounds
EP4358550A4 (en) 2021-07-19 2024-10-16 Kyocera Corporation COMMUNICATION PROCESS
IL310588A (en) * 2021-08-09 2024-04-01 Scorpion Therapeutics Inc Compounds that inhibit PI3K isoform alpha and methods for treating cancer
IL315250A (en) 2022-04-06 2024-10-01 Genentech Inc Combination therapies including GDC-6036 and GDC-0077 for the treatment of cancer
WO2024022435A1 (zh) * 2022-07-27 2024-02-01 南京明德新药研发有限公司 一种5,6-二氢苯并[f]咪唑并[1,2-d][1,4]噁吖庚英化合物的晶型及其制备方法
WO2024100236A1 (en) 2022-11-11 2024-05-16 Astrazeneca Ab Combination therapies for the treatment of cancer
WO2024206147A1 (en) 2023-03-24 2024-10-03 Arvinas Operations, Inc. Dosage regimens of estrogen receptor degraders
TW202506112A (zh) 2023-08-11 2025-02-16 美商建南德克公司 包含經塗覆錠劑之醫藥調配物
US20250177414A1 (en) 2023-12-04 2025-06-05 Genentech, Inc. Combination therapies for treatment of breast cancer
WO2025122745A1 (en) 2023-12-05 2025-06-12 Genentech, Inc. Combination therapies for treatment of her2 cancer

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
GB9208135D0 (en) 1992-04-13 1992-05-27 Ludwig Inst Cancer Res Polypeptides having kinase activity,their preparation and use
US6274327B1 (en) 1992-04-13 2001-08-14 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
US5846824A (en) 1994-02-07 1998-12-08 Ludwig Institute For Cancer Research Polypeptides having kinase activity, their preparation and use
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
KR100785363B1 (ko) * 2000-04-25 2007-12-18 이코스 코포레이션 인간 포스파티딜-이노시톨 3-키나제 델타의 억제제
PT1696931E (pt) 2003-12-22 2009-06-12 Acadia Pharm Inc Análogos diaril[a,d]ciclo-hepteno substituídos com amino utilizados como agonistas muscarínicos e métodos de tratamento de perturbações neuropsiquiátricas
EP2612862B1 (en) 2004-05-13 2016-09-14 Icos Corporation Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
GB0423653D0 (en) 2004-10-25 2004-11-24 Piramed Ltd Pharmaceutical compounds
AU2006242920A1 (en) 2005-05-04 2006-11-09 Pfizer Limited 2-amido-6-amino-8-oxopurine derivatives as Toll-Like receptor modulators for the treatment of cancer and viral infections, such as hepatitis C
PT1934174E (pt) 2005-10-07 2011-07-14 Exelixis Inc Azetidinas como inibidores de mek para o tratamento de doenças proliferativas
HRP20100446T1 (hr) 2006-04-26 2010-09-30 F. Hoffmann-La Roche Ag Derivat tieno[3,2-d]pirimidina koristan kao inhibitor pi3k
GB0610866D0 (en) 2006-06-02 2006-07-12 Hammersmith Imanet Ltd Novel in vivo imaging compounds
SI2526934T1 (sl) 2006-09-22 2016-04-29 Pharmacyclics Llc Inhibitorji Bruton tirozin kinaze
AR064106A1 (es) * 2006-12-05 2009-03-11 Bayer Schering Pharma Ag Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
KR101460816B1 (ko) 2006-12-07 2014-11-12 에프. 호프만-라 로슈 아게 포스포이노시타이드 3-키나제 억제제 화합물 및 그의 사용 방법
EP2225216A1 (en) * 2007-11-21 2010-09-08 Decode Genetics EHF Substituted benzoazole pde4 inhibitors for treating pulmonary and cardiovascular disorders
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
SG10201405049RA (en) * 2009-09-28 2014-10-30 Hoffmann La Roche Benzoxazepin pi3k inhibitor compounds and methods of use
KR20140034948A (ko) 2009-09-28 2014-03-20 에프. 호프만-라 로슈 아게 벤즈옥세핀 ｐｉ3ｋ 억제제 화합물 및 사용 방법
WO2011056930A2 (en) * 2009-11-06 2011-05-12 Emory University Fragile x mental retardation protein (fmrp), compositions, and methods related thereto
WO2012126901A1 (en) 2011-03-21 2012-09-27 F. Hoffmann-La Roche Ag Benzoxazepin compounds selective for pi3k p110 delta and methods of use
CA2840754A1 (en) 2011-07-01 2013-01-10 Novartis Ag Combination therapy comprising a cdk4/6 inhibitor and a pi3k inhibitor for use in the treatment of cancer
NO3175985T3 (es) 2011-07-01 2018-04-28
UY34632A (es) 2012-02-24 2013-05-31 Novartis Ag Compuestos de oxazolidin- 2- ona y usos de los mismos
MX2014010656A (es) 2012-03-05 2015-03-03 Gilead Calistoga Llc Formas polimorficas de (s)-2-(1-(9h-purin-6-ilamino)propil)-5-fluo ro-3-fenilquinazolin-4(3h)-ona.
EP2834033A4 (en) * 2012-03-30 2016-01-20 Univ Brigham Young EXPANSION MODULATION FOR PROCESS CONTROL OF FRAME WELDING OPERATIONS
KR101909801B1 (ko) 2012-06-08 2018-10-18 에프. 호프만-라 로슈 아게 암의 치료를 위한 포스포이노시타이드 3 키나제 억제제 화합물 및 화학치료제의 돌연변이체 선택성 및 조합물
EP3845540A1 (en) * 2013-03-13 2021-07-07 F. Hoffmann-La Roche AG Intermediates for the synthesis of benzoxazepin compounds
JP6260967B2 (ja) * 2013-11-06 2018-01-17 国立大学法人京都大学 放射性ヨウ素標識化合物、及び、これを含む放射性医薬
TW202108592A (zh) 2015-07-02 2021-03-01 瑞士商赫孚孟拉羅股份公司 苯并氧氮呯噁唑啶酮化合物及其用途
US9643980B2 (en) 2015-07-02 2017-05-09 Genentech, Inc. Benzoxazepin oxazolidinone compounds and methods of use
SI3555107T1 (sl) 2016-12-15 2021-07-30 F. Hoffmann-La Roche Ag Postopek za pripravo (S)-2-((2-((S)-4(difluorometil)-2-oksooksazolidin-3-il)-5,6-dihidrobenzo (f)imidazo(1,2-d)(1,4)oksazepin-9-il)amino) propanamida
US20180339997A1 (en) * 2017-04-28 2018-11-29 Genentech, Inc. Polymorphs and solid forms of (s)-2-((2-((s)-4-(difluoromethyl)-2-oxooxazolidin-3-yl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepin-9-yl)amino)propanamide, and methods of production
AU2019310335A1 (en) 2018-07-23 2021-02-11 F. Hoffmann-La Roche Ag Methods of treating cancer with PI3K inhibitor, GDC-0077
WO2020076432A1 (en) 2018-10-08 2020-04-16 Genentech, Inc. Methods of treating cancer with pi3k alpha inhibitors and metformin
WO2021113219A1 (en) 2019-12-03 2021-06-10 Genentech, Inc. Combination therapies for treatment of breast cancer

Also Published As

Publication number Publication date
TWI601732B (zh) 2017-10-11
PH12020551315A1 (en) 2021-07-05
TWI649326B (zh) 2019-02-01
US10112932B2 (en) 2018-10-30
KR102014326B1 (ko) 2019-08-26
JP2019178135A (ja) 2019-10-17
MA54252A (fr) 2022-04-27
UA121678C2 (uk) 2020-07-10
MY195002A (en) 2022-12-30
US20170015678A1 (en) 2017-01-19
SG10201913980SA (en) 2020-03-30
PE20211775A1 (es) 2021-09-08
TWI698440B (zh) 2020-07-11
CN112047960A (zh) 2020-12-08
RU2018103454A (ru) 2019-08-05
TW202108592A (zh) 2021-03-01
US20170210733A1 (en) 2017-07-27
MA42295B1 (fr) 2020-02-28
IL255200B (en) 2020-05-31
MX388533B (es) 2025-03-20
JP6880101B2 (ja) 2021-06-02
AU2016287463A1 (en) 2017-10-26
MX2017016344A (es) 2018-05-02
EP3778607B1 (en) 2023-08-30
PL3317284T3 (pl) 2020-04-30
AU2016287463B2 (en) 2020-07-02
EP3317284A1 (en) 2018-05-09
EP3317284B1 (en) 2019-10-30
EP3778607C0 (en) 2023-08-30
KR102306071B1 (ko) 2021-10-01
CN107873032A (zh) 2018-04-03
AR105238A1 (es) 2017-09-20
EP4212536B1 (en) 2025-02-19
EP3567045B1 (en) 2022-01-12
CA2982708A1 (en) 2017-01-05
LT3317284T (lt) 2020-01-27
TW201936612A (zh) 2019-09-16
CR20170563A (es) 2018-02-20
WO2017001645A1 (en) 2017-01-05
PL3567045T3 (pl) 2022-04-19
JP2018519307A (ja) 2018-07-19
PE20181021A1 (es) 2018-06-27
MX372624B (es) 2020-05-07
RS59740B1 (sr) 2020-02-28
EP4212536C0 (en) 2025-02-19
US9650393B2 (en) 2017-05-16
CN107873032B (zh) 2020-07-17
CA2982708C (en) 2023-10-03
US20250197386A1 (en) 2025-06-19
JP6523490B2 (ja) 2019-06-05
JP7266630B2 (ja) 2023-04-28
NZ775526A (en) 2024-05-31
EP4212536A1 (en) 2023-07-19
US20180127404A1 (en) 2018-05-10
TW201712020A (zh) 2017-04-01
RU2018103454A3 (es) 2019-11-21
ZA201808370B (en) 2023-03-29
CN111909173A (zh) 2020-11-10
CO2017011038A2 (es) 2018-02-09
KR20180006460A (ko) 2018-01-17
PT3317284T (pt) 2020-01-10
BR112017023121A2 (pt) 2018-07-10
ES2764497T3 (es) 2020-06-03
US11760753B2 (en) 2023-09-19
JP2023103242A (ja) 2023-07-26
ES2908300T3 (es) 2022-04-28
US10851091B2 (en) 2020-12-01
CL2017003436A1 (es) 2018-05-04
EP3567045A1 (en) 2019-11-13
PH12017502425A1 (en) 2018-07-02
US20210246129A1 (en) 2021-08-12
RU2730529C2 (ru) 2020-08-24
AU2020204418A1 (en) 2020-07-23
IL272277A (en) 2020-02-27
DK3317284T3 (da) 2020-01-13
CN112062778B (zh) 2024-04-19
AU2020204418B2 (en) 2022-02-03
CN111909173B (zh) 2025-03-04
EP3778607A1 (en) 2021-02-17
KR20190100432A (ko) 2019-08-28
US20240199594A1 (en) 2024-06-20
EP4585597A1 (en) 2025-07-16
MA49861A (fr) 2021-05-05
CN112047960B (zh) 2024-08-02
JP2021119144A (ja) 2021-08-12
HRP20192349T1 (hr) 2020-03-20
TW201815798A (zh) 2018-05-01
IL277774A (en) 2020-11-30
HUE046756T2 (hu) 2020-03-30
US20190263793A1 (en) 2019-08-29
SI3317284T1 (sl) 2020-02-28
IL272277B (en) 2021-01-31
NZ736222A (en) 2024-05-31
HK1253003A1 (zh) 2019-06-06
IL255200A0 (en) 2017-12-31
CN112062778A (zh) 2020-12-11

Similar Documents

Publication Publication Date Title
MX2020003415A (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso.
DOP2019000168A (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
CO2017004481A2 (es) Compuestos de indol carboxamida utiles como inhibidores de cinasas
CR20150628A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CO2019010078A2 (es) Compuestos de pirimidinil-pyridiloxi-naftil y métodos para tratar enfermedades y trastornos relacionados con ire1
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
MX381313B (es) Derivados de benzimidazol como moduladores de ror-gamma
ECSP16005566A (es) Sulfonamidas como moduladores de canales de sodio
MX2017007489A (es) Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos.
CO2018004857A2 (es) Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer
BR112015022191A2 (pt) compostos heteroarila, seu uso e composição que os compreende
TR201904455T4 (tr) Nükleer taşıma modülatörleri olarak 1,2,4-triazoller ve bunların kullanımları.
PE20151438A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
CL2019002900A1 (es) Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton.
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
UY36875A (es) Composiciones inhibidoras de bromodominios para el tratamiento de diversas enfermedades
MX2018004664A (es) Antagonistas de ep4.
UY35419A (es) Inhibidores de cdk9 quinasa de pirrolo (2,3- b) piridina
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
UY36608A (es) Derivados de indol
AR122456A2 (es) Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos
ECSP099644A (es) Derivados de quinolina, composiciones farmacéuticas que los comprenden y el uso de tales en el tratamiento de enfermedades del sistema nervioso central y periférico
AR105921A1 (es) Compuestos terapéuticos para el dolor y síntesis de estos